AB

ABBV

NYSE

AbbVie Inc.

Healthcare
Drug Manufacturers - General
United States
256.91USD
-2.45 (-0.94%)
Market Cap: 453.91B USD

Revenue and Net Income

Values in USD

Income Statement

Values in USD

Financial itemTTMMar 31, 2026Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Total Revenue
62.82B61.16B56.33B54.32B58.05B
Cost of Revenue
18.42B18.20B16.90B20.41B17.41B
Gross Profit
44.40B42.96B39.43B33.90B40.64B
Operating Expense
23.55B22.86B27.54B20.37B21.83B
Operating Income
20.84B20.09B11.89B13.54B18.81B
Net Non Operating Interest Income Expense
-2.65B-2.63B-2.16B-1.68B-2.04B
Other Income Expense
-12.22B-10.87B-6.02B-5.60B-3.29B
Pretax Income
5.97B6.60B3.72B6.25B13.48B
Tax Provision
2.33B2.36B-570.00M1.38B1.63B
Net Income Common Stockholders
3.60B4.19B4.24B4.82B11.78B
Diluted NI Available to Com Stockholders
3.60B4.19B4.24B4.82B11.78B
Basic EPS
2.042.372.422.756.69
Diluted EPS
2.042.372.392.726.63
Basic Average Shares
1.77B1.77B1.77B1.77B1.77B
Diluted Average Shares
1.77B1.77B1.77B1.77B1.78B
Total Operating Income as Reported
15.33B15.07B9.14B12.76B18.12B
Total Expenses
41.98B41.07B44.44B40.78B39.24B
Net Income from Continuing & Discontinued Operation
3.63B4.23B4.28B4.86B11.84B
Normalized Income
7.03B7.48B6.47B5.58B12.58B
Interest Income
265.00M266.00M648.00M540.00M186.00M
Interest Expense
2.91B2.89B2.81B2.22B2.23B
Net Interest Income
-2.65B-2.63B-2.16B-1.68B-2.04B
EBIT
8.88B9.49B6.52B8.47B15.71B
EBITDA
16.92B17.63B14.91B17.17B24.17B
Reconciled Cost of Revenue
18.42B18.20B16.90B20.41B17.41B
Reconciled Depreciation
8.04B8.14B8.39B8.70B8.47B
Net Income from Continuing Operation Net Minority Interest
3.63B4.23B4.28B4.86B11.84B
Total Unusual Items Excluding Goodwill
-5.57B-5.07B-2.78B-924.00M-845.00M
Total Unusual Items
-5.57B-5.07B-2.78B-924.00M-845.00M
Normalized EBITDA
22.49B22.70B17.69B18.10B25.02B
Tax Rate for Calcs
0.390.360.210.220.12
Tax Effect of Unusual Items
-2.18B-1.82B-583.38M-203.28M-102.25M

Key Statistics

Valuation

Market Cap (USD)453.91B
Market Cap (Local)453.91B
P/E (TTM)126.26
P/S (TTM)7.23
MC/EBITDA26.83

Volume & Shares

Last Volume5.40M
Avg Vol (10D)4.53M
Avg Vol (30D)6.04M
Avg Vol (90D)6.80M
Shares Outstanding1.77B

Growth Indicators

Revenue TTM/Ann1.03
Net Income TTM/Ann0.85
EBITDA TTM/Ann0.96
Gross Profit TTM/Ann1.03
Operating Inc TTM/Ann1.04

Currency & Exchange

Trading CurrencyUSD
Financial CurrencyUSD
Trading/USD Rate1.00
Financial/USD Rate1.00
ExchangeNYSE

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases Rinvoq to treat inflammatory diseases Imbruvica for the treatment of adult patients with blood cancers Venclexta to treat blood cancers Elahere to treat various cancer and Epkinly to treat lymphoma and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder Duodopa to treat Parkinson's disease Ubrelvy to treat migraine Qulipta for episodic and chronic migraine and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection Creon, a pancreatic enzyme therapy and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.